vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Excelerate Energy, Inc. (EE). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $317.6M, roughly 1.5× Excelerate Energy, Inc.). On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 15.7%). Over the past eight quarters, Excelerate Energy, Inc.'s revenue compounded faster (26.0% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Excelerate Energy, Inc. is a global leading provider of flexible liquefied natural gas (LNG) solutions, offering floating storage and regasification units, LNG delivery services and integrated infrastructure projects. It serves utility and industrial clients across Europe, Asia, Latin America and the Middle East, supporting markets to achieve accessible low-carbon energy transitions.

CLOV vs EE — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.5× larger
CLOV
$487.7M
$317.6M
EE
Growing faster (revenue YoY)
CLOV
CLOV
+29.1% gap
CLOV
44.7%
15.7%
EE
Faster 2-yr revenue CAGR
EE
EE
Annualised
EE
26.0%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
EE
EE
Revenue
$487.7M
$317.6M
Net Profit
$-49.3M
Gross Margin
Operating Margin
-10.1%
22.2%
Net Margin
-10.1%
Revenue YoY
44.7%
15.7%
Net Profit YoY
-123.2%
EPS (diluted)
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
EE
EE
Q4 25
$487.7M
$317.6M
Q3 25
$496.6M
$391.0M
Q2 25
$477.6M
$204.6M
Q1 25
$462.3M
$315.1M
Q4 24
$337.0M
$274.6M
Q3 24
$331.0M
$193.4M
Q2 24
$356.3M
$183.3M
Q1 24
$346.9M
$200.1M
Net Profit
CLOV
CLOV
EE
EE
Q4 25
$-49.3M
Q3 25
$-24.4M
Q2 25
$-10.6M
Q1 25
$-1.3M
Q4 24
$-22.1M
Q3 24
$-9.2M
Q2 24
$7.4M
Q1 24
$-19.2M
Gross Margin
CLOV
CLOV
EE
EE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
CLOV
CLOV
EE
EE
Q4 25
-10.1%
22.2%
Q3 25
-4.9%
22.3%
Q2 25
-2.2%
21.2%
Q1 25
-0.3%
20.9%
Q4 24
-6.4%
21.9%
Q3 24
-2.7%
30.9%
Q2 24
2.0%
27.2%
Q1 24
-6.5%
22.6%
Net Margin
CLOV
CLOV
EE
EE
Q4 25
-10.1%
Q3 25
-4.9%
Q2 25
-2.2%
Q1 25
-0.3%
Q4 24
-6.6%
Q3 24
-2.8%
Q2 24
2.1%
Q1 24
-5.5%
EPS (diluted)
CLOV
CLOV
EE
EE
Q4 25
$0.24
Q3 25
$0.43
Q2 25
$0.15
Q1 25
$0.46
Q4 24
$0.42
Q3 24
$0.35
Q2 24
$0.26
Q1 24
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
EE
EE
Cash + ST InvestmentsLiquidity on hand
$78.3M
$538.2M
Total DebtLower is stronger
$936.3M
Stockholders' EquityBook value
$308.7M
$2.2B
Total Assets
$541.0M
$4.1B
Debt / EquityLower = less leverage
0.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
EE
EE
Q4 25
$78.3M
$538.2M
Q3 25
$462.6M
Q2 25
$426.0M
Q1 25
$619.5M
Q4 24
$194.5M
$537.5M
Q3 24
$288.0M
$608.4M
Q2 24
$254.8M
$609.1M
Q1 24
$208.3M
$578.9M
Total Debt
CLOV
CLOV
EE
EE
Q4 25
$936.3M
Q3 25
$942.0M
Q2 25
$946.2M
Q1 25
$322.6M
Q4 24
$333.6M
Q3 24
$345.7M
Q2 24
$356.4M
Q1 24
$366.9M
Stockholders' Equity
CLOV
CLOV
EE
EE
Q4 25
$308.7M
$2.2B
Q3 25
$340.9M
$2.2B
Q2 25
$344.2M
$2.1B
Q1 25
$336.1M
$1.9B
Q4 24
$341.1M
$1.9B
Q3 24
$342.2M
$1.9B
Q2 24
$324.9M
$1.8B
Q1 24
$292.5M
$1.8B
Total Assets
CLOV
CLOV
EE
EE
Q4 25
$541.0M
$4.1B
Q3 25
$559.7M
$4.1B
Q2 25
$575.0M
$4.0B
Q1 25
$583.7M
$2.9B
Q4 24
$580.7M
$2.9B
Q3 24
$653.0M
$2.9B
Q2 24
$674.2M
$2.9B
Q1 24
$671.8M
$2.9B
Debt / Equity
CLOV
CLOV
EE
EE
Q4 25
0.42×
Q3 25
0.43×
Q2 25
0.44×
Q1 25
0.17×
Q4 24
0.18×
Q3 24
0.18×
Q2 24
0.19×
Q1 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
EE
EE
Operating Cash FlowLast quarter
$-66.9M
$104.4M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
EE
EE
Q4 25
$-66.9M
$104.4M
Q3 25
$12.1M
$114.9M
Q2 25
$5.4M
$87.1M
Q1 25
$-16.3M
$154.8M
Q4 24
$34.8M
$49.6M
Q3 24
$50.0M
$39.8M
Q2 24
$44.8M
$90.4M
Q1 24
$25.9M
$64.7M
Free Cash Flow
CLOV
CLOV
EE
EE
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
Q2 24
$44.4M
Q1 24
$25.5M
FCF Margin
CLOV
CLOV
EE
EE
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
Q2 24
12.5%
Q1 24
7.3%
Capex Intensity
CLOV
CLOV
EE
EE
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
CLOV
CLOV
EE
EE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

EE
EE

Other$179.4M57%
Revenue From Leases$138.1M43%

Related Comparisons